[Multidisciplinary meeting about the use of direct oral anticoagulants in nonvalvular atrial fibrillation]

Abstract

Knowing the real impact of atrial fibrillation in the stroke, the Sociedad Mexicana of Electrofisiología y Estimulación Cardiaca (SOMEEC) had the initiative to develop a multidisciplinary meeting of experts the with the purpose to update the available scientific evidence from clinical practice guidelines, meta-analyses, controlled clinical trials, and complementing with the experience and views of a group of experts. To meet this goal, SOMEEC gathered a group of specialists in the area of cardiology, electrophysiology, neurology and hematology that given their experience in certain areas, they share the scientific evidence with the panel of experts to leave open a discussion about the information presented in this article. This document brings together the best scientific evidence available and aims to be a useful tool in the decision to use of new oral anticoagulants in nonvalvular atrial fibrillation and ischemic heart disease, or relating to the management of patients with stroke or renal failure, and even those that will be submitted to elective surgery and invasive procedures. In the same, they handled comparative schemes of follow-up and treatment which simplifies the decision making by the specialists participants.

Keywords: Anticoagulantes orales; Apixaban; Apixabán; Atrial fibrillation; Dabigatran; Dabigatrán; Fibrilación auricular; Mexico; México; Oral anticoagulants; Rivaroxaban; Rivaroxabán; Sociedad Mexicana de Electrofisiología y Estimulación Cardiaca.